Fondaparinux sodium
Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII) . (In Vitro) :Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs) . (In Vivo) :Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation.
Product Specifications
CAS Number
114870-03-0
Product Name Alternative
Fondaparinux sodium | PENTA | Arixtra
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
H2O : ≥ 30 mg/mL 17.26 mM
Smiles
Molecular Formula
C31H44N3Na10O49S8
Molecular Weight
1729.09
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog